Emmessar Biotech — 360° view

Emmessar Biotech, a company in the Commodity Chemicals industry, reported revenue of ₹0.11 crore and net profit of ₹0.14 crore for the September 2026 quarter.

Emmessar Biotech (BSE: EMMESSA) closed at ₹29.50 on 20 Nov 2026, down 4.8% over the past year. Its market capitalisation is ₹15 crore and it trades at 35.1 times earnings.

Share price
₹29.50 (20 Nov 2026)
Market cap
₹15 Cr (20 Nov 2026)
P/E
35.12 (20 Nov 2026)
Revenue
₹0 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
7.33% (FY26)
ROE
5.56% (FY26)
Book value
₹16.8 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹32.60 / ₹18.42 (20 Nov 2026)
1-year return
-4.8% (to 20 Nov 2026)
Sector
Commodities
Industry
Commodity Chemicals
Symbol
BSE: EMMESSA

Emmessar Biotech & Nutrition Ltd is a standalone healthcare-products and property-leasing company. It manufactures /trades a small VedaCeuticals portfolio and earns rent from sub-leasing its MIDC Taloja industrial land; FY26 filings report Healthcare and Rent on Leasehold Land as the only operating segments.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.